Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

Immunotherapy for Treatment of Neuromyelitis Optica (NMO)

This invention comprises compositions and methods for treatment of neuromyelitis optica (NMO) spectrum disorders using anti-aquaporin-4 (AQP4) antibody lacking effector function.

EpiSort: A Novel Method Using Deep Bisulfite Sequencing to Determine Immune Cell Types in Solid Tissue Samples

EpiSort is a novel method of using DNA methylation patterns to determine the proportion of immune cell populations in solid tissue samples.

An Optimized Active Decapping Complex for Transcription Start Site Mapping

This invention describes an optimized, constitutive active decapping complex from S. pombe for efficient transcription start site (TSS) mapping.

NANOKNIFE AND MEMS PLATFORM FOR MICROSURGERY

A microsurgical device for precise cutting and manipulation of damaged axons to reconstitute nerve function.

TREATING TYPE-1 DIABETES BY PRESERVING BETA CELL FUNCTION

This invention proposes the first pharmacological treatment to prevent the onset of Type I diabetes by preventing beta cell destruction. 

Novel Methodology To Convert Magnetic Resonance Imaging Scan Data To Be Used In Proton Beam Therapy

This invention is a novel model that uses magnetic resonance imaging (MRI) information to more accurately determine the irradiation area using proton beam therapy (PBT) for oncological treatment.

Percutaneous Arteriovenous Fistula For Dialysis Access

This implantable medical device can be used to create an arteriovenous fistula (AVF) percutaneously, in a clinic based procedure. The AVF improves clinical outcomes for  patients  on hemodialysis.

Structurally Validated Anti-avß8 Antibodies for Targeting TGFß for Immunotherapy

This invention provides highly efficient antibodies whose epitopes and mechanism of action have been structurally defined against integrin αvβ8. These antibodies have been designed to be used as therapeutic for cancer. Other antibodies have been designed as companion diagnostic tools.

These technologies are part of the UC QuickStart program.